Olema Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Good morning. My name is Arlinda Lee and I'm a senior analyst on Canaccord's biotech team. I'm pleased Olema's President and Chief Executive Officer, Sean Bohen, is joining us today for a fireside chat to talk about Olema's dual SERD CERAN OP-1250 and its clinical development. Sean, welcome.
Thank you, Arlinda, and thank you for having me.
Questions & Answers
Great. Let's start talking about Olema's 1250. It's currently in monotherapy dose escalation -- dose expansion at the 60 milligram and 120 milligram doses. How do you -- what are the criteria that you're going to use to select the recommended Phase 2 dose and when do you expect to do that?
Yeah. So the criteria mainly will be an expansion of tolerability and an expansion of our information with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
